605681-01-4

Usage

Uses

Used in Pharmaceutical Industry:
Pyridine, 2-(bromomethyl)-5-chloro(9CI) is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to be easily modified and incorporated into complex molecular structures. Its presence in the molecular framework can influence the pharmacological properties of the final drug, such as solubility, stability, and bioavailability.
Used in Agrochemical Industry:
In the agrochemical sector, Pyridine, 2-(bromomethyl)-5-chloro(9CI) serves as a building block for the development of new pesticides and herbicides. Its halogenated nature allows for the creation of compounds with specific targeting and biological activity against pests and weeds, enhancing crop protection strategies.
Used in Organic Synthesis:
Pyridine, 2-(bromomethyl)-5-chloro(9CI) is utilized as a versatile reagent in organic synthesis for its potential to participate in a variety of chemical reactions, such as nucleophilic substitutions, addition reactions, and cross-coupling reactions. This makes it a valuable component in the preparation of complex organic molecules and advanced materials.
Used in Fine Chemicals Production:
Pyridine, 2-(bromomethyl)-5-chloro(9CI) is also employed in the production of fine chemicals, which are high-purity chemicals used in various applications, including research, diagnostics, and specialty manufacturing. Its unique structure and reactivity contribute to the synthesis of high-value specialty chemicals with specific applications in different industries.

Upstream product

• 86873-60-1 5-chloropicolinic acid 
• 16110-09-1 2,5 dichloropyridine 
• 132308-19-1 methyl 5-chloropyridine-2-carboxylate 
• 209526-98-7 (5-chloro-2-pyridinyl)methanol 
• 72093-07-3 2-methyl-5-chloropyridine 
• 128072-93-5 ethyl 5-chloropyridine-2-carboxylate 

Downstream Products

• 605681-00-3 3-(3-bromophenyl)-4-(5-chloro-2-pyridyl)-2-butanone 
• 1184949-79-8 4-(5-chloro-pyridin-2-ylmethoxy)-1-[2-(4-hydroxymethyl-phenyl)-2-oxo-ethyl]-1H-pyridin-2-one 
• 1453500-01-0 4-(5-chloro-pyridin-2-ylmethoxy)-1-[2-(4-hydroxymethyl-2-methyl-phenyl)-2-oxo-ethyl]-1H-pyridin-2-one 
• 1184946-43-7 4-(5-chloro-pyridin-2-ylmethoxy)-1-[2-(4-dimethylaminomethyl-phenyl)-2-oxo-ethyl]-1H-pyridin-2-one 
• 1453499-28-9 4-((5-chloropyridin-2-yl)methoxy)-1-(2-(4-((dimethylamino)methyl)-2-methylphenyl)-2-oxoethyl)pyridin-2(1H)-one 
• 1184949-77-6 1-[2-(4-bromomethyl-phenyl)-2-oxo-ethyl]-4-(5-chloro-pyridin-2-ylmethoxy)-1H-pyridin-2-one 
• 1453500-02-1 1-[2-(4-bromomethyl-2-methyl-phenyl)-2-oxo-ethyl]-4-(5-chloro-pyridin-2-ylmethoxy)-1H-pyridin-2-one 
• 605681-02-5 3-(3-bromophenyl)-4-(5-chloro-2-pyridyl)-2-butanol 

Relevant academic research and scientific papers

NOVEL TETRAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF TUBERCULOSIS

The invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by mycobacterium, such as tuberculosis.

SPIROPYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF FOR THE TREATMENT OF VIRAL INFECTIONS

A compound of Formula (I) is provided that has been shown to be useful for treating a disease caused by a viral infection: (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, X1, X2, X3 and X4, are as defined herein.

1-(DIHYDRONAPHTHALENYL)PYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS

This invention relates to novel 1-(dihydronaphthalenyl)pyridones which are antagonists of the melanin-concentrating hormone receptor 1 (MCHR1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy

4H- [1, 2, 4] TRIAZOLO [5, 1 -B] PYRIMIDIN-7 -ONE DERIVATIVES AS CCR2B RECEPTOR ANTAGONISTS

The present invention relates to novel compounds for use in the compositions, to processes for their preparation, to intermediates useful in their preparation and to their use as therapeutic agents. The present invention also relates to pharmaceutical com

1H-PYRAZOLO [3, 4-B] PYRIDINE COMPOUNDS FOR INHIBITING RAF KINASE

Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. [FORMULA I]

PYRIDONE ANALOGS USEFUL AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS

MCHR1 antagonists are provided having the following Formula I: wherein A1 and A2 are independently C or N; E is C or N; D1 is a bond, -CR8R9X-, -XCR8R9-, -CHR8CHR

SUBSTITUTED SULFONAMIDES

The substituted sulfonamides of the invention are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

ARALKYL AMINES AS CANNABINOID RECEPTOR MODULATORS

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson’s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, including alcohol and nicotine addiction, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

SUBSTITUTED AMIDES ACTIVE AT THE CANNABINOID-1 RECEPTOR

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

SUBSTITUTED ARYL AMIDES

Novel compounds of structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as, the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.